Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous).
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone424-248-6500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$251 million
Profitability
Miscellaneous
Employees272
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions
What is Puma Biotechnology's stock symbol?
Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."
How were Puma Biotechnology's earnings last quarter?
Puma Biotechnology Inc (NASDAQ:PBYI) issued its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by $0.07. The biopharmaceutical company had revenue of $53.90 million for the quarter, compared to analysts' expectations of $53.40 million. Puma Biotechnology had a negative net margin of 32.23% and a negative return on equity of 254.09%. The company's revenue was up 6.1% on a year-over-year basis. During the same period last year, the business earned ($0.59) earnings per share. View Puma Biotechnology's Earnings History.
When is Puma Biotechnology's next earnings date?
What price target have analysts set for PBYI?
10 equities research analysts have issued 1 year price targets for Puma Biotechnology's stock. Their predictions range from $9.00 to $29.00. On average, they anticipate Puma Biotechnology's share price to reach $19.25 in the next year. This suggests a possible upside of 105.2% from the stock's current price. View Analyst Price Targets for Puma Biotechnology.
What is the consensus analysts' recommendation for Puma Biotechnology?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 3 sell ratings and 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Puma Biotechnology.
What are Wall Street analysts saying about Puma Biotechnology stock?
Here are some recent quotes from research analysts about Puma Biotechnology stock:
- 1. According to Zacks Investment Research, "Puma Biotech's only marketed drug, Nerlynx, was approved for early stage HER2-positive breast cancer. The drug has seen improved sales steadily since its launch in July 2017. Nerlynx was also approved in the EU last September and can generate additional sales in 2019. Several further studies on Nerlynx targeting different types of breast cancer patient populations and in earlier-line settings are currently underway. The drug’s label expansion will allow it to treat and access an expanded patient population. Puma Biotech is totally dependent on Nerlynx for growth, hence, any regulatory setback for Nerlynx could affect the growth prospects and weigh heavily on the stock. Shares have outperformed the industry year to date. Loss estimates look stable ahead of Q1 earnings. Puma Biotech has a positive record of earnings surprises in the recent quarters." (5/1/2019)
- 2. Cowen Inc analysts commented, "Cidara reported 4Q18 financial results yesterday and we spoke w/ mgmt for an update. Phase 3 RESTORE trial of rezafungin in Candidemia/ Invasive Candidiasis was initiated last yr and enrollment rate is reportedly in line w/ expectations. Mgmt guiding for top-line results in mid-2020 (unch). Discussions are still ongoing w/ both EMA and FDA around Phase 3 RESPECT trial in prophylaxis. Mgmt nevertheless guiding for initiation in 1H19. Top-line results from Phase 2 STRIVE B trial likely mid-2019. We assume safety/ efficacy profile similar to STRIVE A. Company reported impressive progress w/ a Cloudbreak Influenza candidate last yr and expects to nominate a development candidate 1Q19. BUY. We acknowledge cash constraints, but believe stock does not adequately reflect value of pipeline." (3/1/2019)
- 3. Cantor Fitzgerald analysts commented, ": Reiterate OW rating; increasing PT to $57/share. Nerlynx roared in 4Q, and 2019 guidance beats expectations. US Nerlynx sales were $61M vs. $53M consensus. Although gross to net was lower in 4Q, we think that 4Q represents a solid beat, and we saw growth in bottles of 12%. In addition, the company’s 2019 US guidance of $255-280M announced on the call exceeded expectations of $238M. Lastly, the company had its first cash flow positive quarter at ~$8M. Shares have recovered by 59% from their early November lows, but we think that there remains upside to shares from Nerlynx growth. We spoke to management post call and we highlight some of our key takes below." (2/28/2019)
Has Puma Biotechnology been receiving favorable news coverage?
News headlines about PBYI stock have trended negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Puma Biotechnology earned a daily sentiment score of -2.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Puma Biotechnology.
Are investors shorting Puma Biotechnology?
Puma Biotechnology saw a increase in short interest in the month of July. As of July 15th, there was short interest totalling 7,542,800 shares, an increase of 10.3% from the June 15th total of 6,838,700 shares. Based on an average trading volume of 1,240,000 shares, the days-to-cover ratio is currently 6.1 days. Currently, 23.1% of the shares of the stock are short sold. View Puma Biotechnology's Current Options Chain.
Who are some of Puma Biotechnology's key competitors?
Some companies that are related to Puma Biotechnology include Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), G1 Therapeutics (GTHX), Madrigal Pharmaceuticals (MDGL), Deciphera Pharmaceuticals (DCPH), Enanta Pharmaceuticals (ENTA), Insmed (INSM), Aimmune Therapeutics (AIMT), AnaptysBio (ANAB), Ra Pharmaceuticals (RARX), Heron Therapeutics (HRTX), Turning Point Therapeutics (TPTX) and Phibro Animal Health (PAHC).
What other stocks do shareholders of Puma Biotechnology own?
Who are Puma Biotechnology's key executives?
Puma Biotechnology's management team includes the folowing people:
- Mr. Alan H. Auerbach, Founder, Chairman, Pres, CEO & Sec. (Age 49)
- Dr. Richard P. Bryce, Chief Medical & Scientific Officer (Age 62)
- Mr. Steven Lo, Chief Commercial Officer (Age 52)
- Mr. Charles R. Eyler, Sr. VP of Fin. & Admin. and Treasurer (Age 71)
- Mr. Maximo F. Nougues, CFO & Principal Accounting Officer (Age 50)
Who are Puma Biotechnology's major shareholders?
Puma Biotechnology's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.94%), BlackRock Inc. (6.47%), Orbimed Advisors LLC (1.60%), Nuveen Asset Management LLC (1.56%), Rice Hall James & Associates LLC (1.45%) and Rock Springs Capital Management LP (1.38%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Charles R Eyler and Richard Paul Bryce. View Institutional Ownership Trends for Puma Biotechnology.
Which institutional investors are selling Puma Biotechnology stock?
PBYI stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Price T Rowe Associates Inc. MD, D. E. Shaw & Co. Inc., Parametric Portfolio Associates LLC, Bank of New York Mellon Corp, Rice Hall James & Associates LLC, TD Asset Management Inc. and BlackRock Inc.. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Charles R Eyler and Richard Paul Bryce. View Insider Buying and Selling for Puma Biotechnology.
Which institutional investors are buying Puma Biotechnology stock?
PBYI stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Morgan Stanley, Bogle Investment Management L P DE, Acadian Asset Management LLC, Point72 Asset Management L.P., Candriam Luxembourg S.C.A., Renaissance Technologies LLC and Vanguard Group Inc.. View Insider Buying and Selling for Puma Biotechnology.
How do I buy shares of Puma Biotechnology?
Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Puma Biotechnology's stock price today?
One share of PBYI stock can currently be purchased for approximately $9.38.
How big of a company is Puma Biotechnology?
Puma Biotechnology has a market capitalization of $364.88 million and generates $251 million in revenue each year. The biopharmaceutical company earns $-113,570,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Puma Biotechnology employs 272 workers across the globe.View Additional Information About Puma Biotechnology.
What is Puma Biotechnology's official website?
How can I contact Puma Biotechnology?
Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]
MarketBeat Community Rating for Puma Biotechnology (NASDAQ PBYI)
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe PBYI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PBYI will underperform the S&P 500 over the long term. You may vote once every thirty days.
